Companies › Anthos Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Cardiovascular; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Abelacimab (MAA868) Coagulation factor XI inhibitor | F11 | Phase 3 | Atrial Fibrillation (AF) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05712200 | Abelacimab (MAA868) | Phase 3 | Atrial Fibrillation (AF) | Cardiovascular | Dec 2027 |
| NCT04755283 | Abelacimab (MAA868) | Phase 2 | Atrial Fibrillation (AF) | Cardiovascular | Dec 2028 |
Regeneron Pharmaceuticals Suzhou Alphamab Johnson & Johnson (Janssen) Sirnaomics
CeleCor Therapeutics MedTrace Pharma SPH Qingdao Growful Pharmacetical Hanlim Pharm. Trust Bio-sonics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.